Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for C4 Therapeutics, Inc. (CCCC : NSDQ)
 
 • Company Description   
C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics Inc. is based in WATERTOWN, Mass.

Number of Employees: 121

 
 • Price / Volume Information   
Yesterday's Closing Price: $6.71 Daily Weekly Monthly
20 Day Moving Average: 806,499 shares
Shares Outstanding: 48.80 (millions)
Market Capitalization: $327.43 (millions)
Beta: 2.77
52 Week High: $51.21
52 Week Low: $6.26
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -26.34% -19.29%
12 Week -67.97% -65.25%
Year To Date -79.16% -75.22%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
490 Arsenal Way Suite 200
-
Watertown,MA 02472
USA
ph: 617-231-0700
fax: -
kendra.adams@c4therapeutics.com https://c4therapeutics.com
 
 • General Corporate Information   
Officers
Andrew J. Hirsch - President and Chief Executive Officer
Marc A. Cohen - Executive Chairman
Lauren A. White - Chief Financial Officer
Alain J. Cohen - Director
Bruce Downey - Director

Peer Information
C4 Therapeutics, Inc. (CORR.)
C4 Therapeutics, Inc. (RSPI)
C4 Therapeutics, Inc. (CGXP)
C4 Therapeutics, Inc. (BGEN)
C4 Therapeutics, Inc. (GTBP)
C4 Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 12529R107
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 48.80
Most Recent Split Date: (:1)
Beta: 2.77
Market Capitalization: $327.43 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.68 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.85 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 20.77% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.90
Price/Cash Flow: -
Price / Sales: 7.12
EPS Growth
vs. Year Ago Period: -32.65%
vs. Previous Quarter: -109.68%
Sales Growth
vs. Year Ago Period: 3.07%
vs. Previous Quarter: -61.88%
ROE
03/31/22 - -24.10
12/31/21 - -22.85
09/30/21 - -26.49
ROA
03/31/22 - -18.37
12/31/21 - -17.50
09/30/21 - -19.89
Current Ratio
03/31/22 - 6.45
12/31/21 - 6.36
09/30/21 - 8.47
Quick Ratio
03/31/22 - 6.45
12/31/21 - 6.36
09/30/21 - 8.47
Operating Margin
03/31/22 - -205.47
12/31/21 - -183.23
09/30/21 - -265.03
Net Margin
03/31/22 - -205.47
12/31/21 - -183.23
09/30/21 - -265.03
Pre-Tax Margin
03/31/22 - -205.47
12/31/21 - -183.23
09/30/21 - -265.40
Book Value
03/31/22 - 7.47
12/31/21 - 8.01
09/30/21 - 8.21
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.03
12/31/21 - 0.03
09/30/21 - 0.03
Debt-to-Capital
03/31/22 - 2.72
12/31/21 - 2.69
09/30/21 - 2.59
 

Powered by Zacks Investment Research ©